PPARG and ovarian carcinoma: This discordance between the expression of PPARγ mRNA and protein after TZD treatment has not been observed nor examined previously, however, the levels of PPARγ protein after TZD treatment have been shown to be highly variable between ES-2 and PA-1 ovarian cancer cells [21].